These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 5538163)

  • 1. Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children.
    Finklestein JZ; Scher J; Karon M
    Cancer Chemother Rep; 1970 Feb; 54(1):35-9. PubMed ID: 5538163
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH; Frei E
    Clin Pharmacol Ther; 1971; 12(6):944-54. PubMed ID: 5289712
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia.
    Baguley BC; Falkenhaug EM
    Cancer Chemother Rep; 1971 Jun; 55(3):291-8. PubMed ID: 5286668
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
    Neil GL; Buskirk HH; Moxley TE; Manak RC; Kuentzel SL; Bhuyan BK
    Biochem Pharmacol; 1971 Dec; 20(12):3295-308. PubMed ID: 5002403
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
    Wan SH; Huffman DH; Azarnoff DL; Hoogstraten B; Larsen WE
    Cancer Res; 1974 Feb; 34(2):392-7. PubMed ID: 4521089
    [No Abstract]   [Full Text] [Related]  

  • 6. Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine.
    Dareer SM; Mulligan LT; White V; Tillery K; Mellett LB; Hill DL
    Cancer Treat Rep; 1977; 61(3):395-407. PubMed ID: 406044
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical pharmacology of cytosine arabinoside.
    Slevin ML; Piall EM; Aherne GW; Johnston A; Lister TA
    Haematol Blood Transfus; 1983; 28():70-5. PubMed ID: 6862311
    [No Abstract]   [Full Text] [Related]  

  • 8. Distribution and excretion of cyclocytidine in monkeys, dogs, and rats.
    Hirayama H; Sugihara T; Hamada F; Kanai T; Hikita J
    Gan; 1974 Apr; 65(2):153-61. PubMed ID: 4209835
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cytosine arabinoside as a polyvalent drug in the treatment of acute non-lymphoid leukemias].
    Sánchez Fayos J
    Sangre (Barc); 1986; 31(5):566-73. PubMed ID: 3810411
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytosine arabinoside (NSC-63878) given subcutaneously to patients with cancer.
    Savel H; Burns SL
    Cancer Chemother Rep; 1969 Apr; 53(2):153-6. PubMed ID: 5799419
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside.
    Weinstein HJ; Griffin TW; Feeney J; Cohen HJ; Propper RD; Sallan SE
    Blood; 1982 Jun; 59(6):1351-3. PubMed ID: 7082832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice.
    Liss RH; Neil GL
    Cancer Chemother Rep; 1975; 59(3):501-13. PubMed ID: 1203880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytosine arabinoside in the treatment of leukemic meningitis].
    Galli V; Massolo F
    Haematologica; 1972; 57(12):815-22. PubMed ID: 4219202
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults.
    Bodey GP; Freireich EJ; Monto RW; Hewlett JS
    Cancer Chemother Rep; 1969 Feb; 53(1):59-66. PubMed ID: 5772656
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs.
    Ho DH; Carter CJ; Loo TL; Abbott RL; McBride CM
    Drug Metab Dispos; 1975; 3(4):309-13. PubMed ID: 240662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
    Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.
    Groothuis DR; Benalcazar H; Allen CV; Wise RM; Dills C; Dobrescu C; Rothholtz V; Levy RM
    Brain Res; 2000 Feb; 856(1-2):281-90. PubMed ID: 10677637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective combination treatment of advanced acute lymphocytic leukemia with cytosine arabinoside (NSC-63878) and L-asparaginase (NSC-109229).
    Ortega JA; Finklestein JZ; Ertel I; Hammond D; Karon M
    Cancer Chemother Rep; 1972 Jun; 56(3):363-8. PubMed ID: 19051496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.